- Home
- CNET vs DRMA Comparison
CNET vs DRMA Comparison
Compare CNET & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNET
- DRMA
- Stock Information
- Founded
- CNET 2003
- DRMA 2014
- Country
- CNET Hong Kong
- DRMA United States
- Employees
- CNET N/A
- DRMA N/A
- Industry
- CNET Advertising
- DRMA Biotechnology: Pharmaceutical Preparations
- Sector
- CNET Consumer Discretionary
- DRMA Health Care
- Exchange
- CNET Nasdaq
- DRMA Nasdaq
- Market Cap
- CNET 4.0M
- DRMA 3.6M
- IPO Year
- CNET N/A
- DRMA 2021
- Fundamental
- Price
- CNET $2.00
- DRMA $5.99
- Analyst Decision
- CNET
- DRMA Strong Buy
- Analyst Count
- CNET 0
- DRMA 1
- Target Price
- CNET N/A
- DRMA $10.00
- AVG Volume (30 Days)
- CNET 449.2K
- DRMA 26.0K
- Earning Date
- CNET 08-14-2025
- DRMA 11-12-2025
- Dividend Yield
- CNET N/A
- DRMA N/A
- EPS Growth
- CNET N/A
- DRMA N/A
- EPS
- CNET N/A
- DRMA N/A
- Revenue
- CNET $7,688,000.00
- DRMA N/A
- Revenue This Year
- CNET N/A
- DRMA N/A
- Revenue Next Year
- CNET N/A
- DRMA N/A
- P/E Ratio
- CNET N/A
- DRMA N/A
- Revenue Growth
- CNET N/A
- DRMA N/A
- 52 Week Low
- CNET $0.96
- DRMA $5.04
- 52 Week High
- CNET $4.53
- DRMA $24.90
- Technical
- Relative Strength Index (RSI)
- CNET 72.89
- DRMA 54.71
- Support Level
- CNET $1.39
- DRMA $5.27
- Resistance Level
- CNET $2.78
- DRMA $5.74
- Average True Range (ATR)
- CNET 0.21
- DRMA 0.40
- MACD
- CNET 0.05
- DRMA 0.07
- Stochastic Oscillator
- CNET 43.89
- DRMA 80.17
About CNET ZW Data Action Technologies Inc.
ZW Data Action Technologies Inc is engaged in providing Internet advertising, precision marketing, e-commerce online to offline (O2O) advertising and marketing services as well as related data and technical services to small and medium enterprises in the PRC. It offers a variety channel of advertising and marketing services through its system, including distribution of the right to use search engine marketing services, provision of online advertising placements on its web portals, provision of e-commerce O2O advertising and marketing services, and provision of other related value-added data and technical services to maximize market exposure and effectiveness for clients.
About DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.